News Article | May 23, 2017
As part of continued expansion plans, The CSL Group have recently opened a second office in Nottingham. The company have chosen to locate their new office just off the M1 motorway at Junction 27.
News Article | May 26, 2017
"Every day we take great pride in delivering exceptional service to our customers in the most efficient, safe and sustainable way – and we constantly seek to get better. As we continue to modernize our fleet, we are bringing advanced technologies into our ship and shore operations that will elevate our business for years to come." CSL's Vice-President of Government and Industry Affairs, Kirk Jones accepted the award on behalf of the Company. In a show of support to the future of the industry, he was joined at the CSL table by a group of cadets from the Massachusetts Maritime Academy who are studying international maritime business. The is second time CSL has won a Lloyd's List ship operator award. In 2015, CSL was named the Inland/Coastal/Lakes Operator of the Year. The CSL Group is the largest owner and operator of self-unloading ships in the world. Headquartered in Montreal with divisions operating throughout the Americas, Australia, Europe and Asia, CSL delivers more than 78 million tonnes of cargo annually for customers in the construction, steel, energy and agricultural sectors.
News Article | October 29, 2016
The CSL Group, a Konica Minolta supplier based in Leicester, have just announced the opening of their newly refurbished showroom and demonstration facility.
Wen Y.,CSL Group |
Han L.,CSL Group |
Han L.,Sanofi S.A. |
Palladino G.,CSL Group |
And 5 more authors.
Vaccine | Year: 2015
Influenza vaccines are the primary intervention for reducing the substantial health burden from pandemic and seasonal influenza. Hemagglutinin (HA) is the most important influenza vaccine antigen. Subunit and split influenza vaccines are formulated, released for clinical use, and tested for stability based on an in vitro potency assay, single-radial immunodiffusion (SRID), which selectively detects HA that is immunologically active (capable of eliciting neutralizing or hemagglutination inhibiting antibodies in an immunized subject). The time consuming generation of strain-specific sheep antisera and calibrated antigen standards for SRID can delay vaccine release. The limitation in generating SRID reagents was evident during the early days of the 2009 pandemic, prompting efforts to develop more practical, alternative, quantitative assays for immunologically active HA. Here we demonstrate that, under native conditions, trypsin selectively digests HA produced from egg or mammalian cell in monovalent vaccines that is altered by stress conditions such as reduced pH, elevated temperature, or deamidation, leaving native, pre-fusion HA, intact. Subsequent reverse-phase high pressure liquid chromatography (RP-HPLC) can separate trypsin-resistant HA from the digested HA. Integration of the resulting RP-HPLC peak yields HA quantities that match well the values obtained by SRID. Therefore, trypsin digestion, to pre-select immunologically active HA, followed by quantification by RP-HPLC is a promising alternative in vitro potency assay for influenza vaccines. © 2015 Elsevier Ltd.
News Article | November 16, 2016
MONTREAL, Nov. 16, 2016 /PRNewswire/ - The CSL Group is pleased to announce that CSL President and CEO, Rod Jones was selected as co-Personality of the Year by the Women's International Shipping and Trading Association (WISTA) during the organization's annual conference last week....